Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions
TraumaVascular System Injury
Interventions
BIOLOGICAL

Human Acellular Vessel (HAV)

The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.

Trial Locations (32)

19104

Penn Presbyterian Medical Center, Philadelphia

19140

Temple University Hospital, Philadelphia

21201

R Adams Cowley Baltimore Shock Trauma, Baltimore

21224

Johns Hopkins Bayview Medical Center, Baltimore

21287

Johns Hopkins Hospital, Baltimore

22908

University of Virginia Health System, Charlottesville

27157

Atrium Health Wake Forest Baptist Medical Center, Winston-Salem

Wake Forest School of Medicine, Winston-Salem

27705

Duke University Hospital, Durham

30303

Grady Memorial Hospital, Atlanta

32209

UF Health Jacksonville, Jacksonville

33136

Jackson South Medical Center, Miami

Ryder Trauma Center, Miami

33606

Tampa General Hospital, Tampa

37232

Vanderbilt University Medical Center, Nashville

55905

Mayo Clinic, Rochester

63110

Saint Louis University (SLU), St Louis

78701

The University of Texas - Dell Medical School, Austin

80204

Ernest E Moore Shock Trauma Center at Denver Health, Denver

90033

Keck Hospital of University of Southern California (USC), Los Angeles

90048

Cedars-Sinai Medical Cener, Los Angeles

92037

Jacob Medical Center at UC San Diego, La Jolla

92103

University of California San Diego (UCSD) Medical Center, San Diego

92868

UCI Medical Center, Orange

95817

University California, Davis, Sacramento

97239

Oregon Health & Science University, Portland

3109601

Rambam Health Care Campus - Vascular Surgery Department, Haifa

5265601

The Chaim Sheba Medical Center - Vascular Surgery Department, Ramat Gan

8410101

Soroka Medical Center - Vascular Surgery Department, Beersheba

9103102

Shaare Zedek Medical Center, Jerusalem

08103

Cooper University Hospital, Camden

07103

Rutgers New Jersey Medical School, Newark

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Atlantic Research Group

OTHER

collaborator

U.S. Army Medical Research and Development Command

FED

lead

Humacyte, Inc.

INDUSTRY

NCT03005418 - Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma | Biotech Hunter | Biotech Hunter